Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 16Carcinoma, Renal Cell 13Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 6Clear-cell metastatic renal cell carcinoma 6Lung Neoplasms 5Prostatic Neoplasms 4Myelodysplastic Syndromes 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Ovarian Neoplasms 3Leukemia, Myeloid, Acute 3Histiocytoma, Malignant Fibrous 3Carcinoma, Transitional Cell 3Carcinoma, Basal Cell 3Urogenital Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2Penile Neoplasms 2Nasopharyngeal Carcinoma 2Meningioma 2Lymphoma 2Hematologic Neoplasms 2Glioblastoma 2Carcinoma, Merkel Cell 2

Interventions

Cyclophosphamide 43venetoclax 30Cytarabine 25fludarabine 22fludarabine phosphate 17Azacitidine 16Mycophenolic Acid 13Whole-Body Irradiation 12Dexamethasone 12Rituximab 11Busulfan 11ruxolitinib 10Vincristine 10Methotrexate 10Etoposide 10Tacrolimus 9Mercaptopurine 9Daunorubicin 9Prednisone 8Filgrastim 8Dasatinib 8ibrutinib 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Granulocyte Colony-Stimulating Factor 7Doxorubicin 7Decitabine 7pegaspargase 6blinatumomab 6Mesna 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × CTLA-4 Antigen × 1 year × Clear all
NCT02530463 2026-03-05

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
99 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡